Form 4: Precision BioSciences CFO John Alexander Kelly Reports RSU Vesting
SEC Form 4 Filing
John Alexander Kelly, CFO of Precision BioSciences, reports the vesting of Restricted Stock Units (RSUs) on March 3, 2025, according to a Form 4 filing with the SEC.
Summary
- A Form 4 filing with the SEC indicates that John Alexander Kelly, the Chief Financial Officer of Precision BioSciences, had Restricted Stock Units (RSUs) vest on March 3, 2025.
- The vesting involved 1,702 RSUs, each representing a contingent right to receive one share of Precision BioSciences' Common Stock.
- Following the reported transaction, Kelly directly owns 86,256 shares of Common Stock.
- The RSUs were granted on March 3, 2022, and vested in three substantially equal annual installments beginning on March 3, 2023, with full vesting occurring on March 3, 2025, contingent upon continued service to the Issuer.
Sentiment
Score: 5
Explanation: This is a neutral event related to executive compensation. It doesn't indicate positive or negative performance for the company.
Industry Context
This is a routine SEC filing related to executive compensation and is typical for publicly traded companies.
Stakeholder Impact
- The vesting of RSUs impacts the CFO's ownership stake in the company.
Key Dates
| Date | Description |
|---|---|
| 03/03/2022 | Reporting Person was granted RSUs |
| 03/03/2023 | First vesting date of RSUs |
| 03/03/2025 | RSUs vested in full |
| 03/05/2025 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.